An FDA Panel Just Voted to Let Pharmacies Make Six Peptides

On July 23, 2026, a committee of outside advisors to the US Food and Drug Administration voted to recommend six peptides for the list of bulk substances that compounding pharmacies are allowed to work with. The six are BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon.

If you have been following the compounding fight we wrote about earlier this year in our piece on the FDA peptide compounding review, this is the moment that review was building toward. It is a real shift. It is also being reported online in ways that overstate what happened, so it is worth walking through carefully.

What the vote actually was

The committee is called the Pharmacy Compounding Advisory Committee. Its job is to advise the FDA on which raw ingredients compounding pharmacies may use to make medicines that are not commercially available. Being on that list, known as the 503A Bulks List, is what makes it clearly legal for a pharmacy to prepare something for a patient.

The votes were not landslides. On BPC-157, eight members voted yes, six voted no, and one abstained. That is about as close as a recommendation gets.

More striking is who the panel disagreed with. FDA staff scientists had reviewed the evidence and recommended against, pointing to studies that were short, small, and underpowered, meaning too few participants to show reliably whether the treatment works or is safe. The committee went the other way. It was the sixth time in a row the panel has voted against its own agency's written recommendation.

Three things this does not mean

This is where most of the coverage goes wrong, so it is worth being blunt.

It is not an approval. None of these six peptides became an approved medicine. Approval means a drug has been through clinical trials proving it is safe and effective for a specific condition. That did not happen here. The vote is about whether pharmacies may prepare the raw ingredient, which is a completely different question.

It is not binding. The committee advises. The FDA decides. The agency is not required to follow the recommendation, and given that its own reviewers argued the other way, there is genuine uncertainty about what it will do.

It is not immediate. Even in the best case for the peptides, the path runs through several steps: removal from the restricted category, then the formal rulemaking process with a public comment period, then placement on the permitted list. People who follow this process closely put that at roughly eight to twelve months before anything is unambiguously legal.

The evidence did not change

The most important thing to hold onto is that no new science arrived in July. The same studies that existed in June existed in July. What changed was a committee's judgment about how to weigh them.

For BPC-157 and TB-500 in particular, that evidence base is thin, and we went through it in detail in our look at what the human research actually shows. Almost all of it is animal work. Fewer than thirty people have taken BPC-157 in published human studies. A regulatory vote does not add a single participant to that count.

It is reasonable to argue, as some committee members did, that patients are already buying these peptides from unregulated sellers and that a compounding pharmacy is a safer place to get them. That is an argument about harm reduction and product quality, not an argument that the peptides work.

What changes for you

In the short term, very little. Nothing about the legal situation changed the day of the vote, and it will not change until the FDA acts.

Over the next year, if the agency follows the recommendation, the likely effect is that these six peptides become available through licensed compounding pharmacies with a prescription, rather than through research chemical sellers. That would mean pharmacy-grade preparation and a pharmacist in the loop, which is a genuine improvement in product quality.

What it would not mean is that anyone has demonstrated these peptides do what they are marketed to do. Keep those two things separate, because the marketing over the next year will work hard to blur them.

Sources: FDA: July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee and STAT News coverage of the vote.